Ftse Mib
36.280,29
0,03%
DAX
21.022,98
0,60%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
107.353,29
4,11%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ XBiotech Inc (XBIT) XBiotech Inc (XBIT) Notizie

XBIT

XBiotech (XBIT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XBIT
DataOraFonteTitoloSimboloCompagnia
31/12/202421:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
23/12/202415:00GlobeNewswire Inc.XBiotech Pauses Rheumatology programNASDAQ:XBITXBiotech Inc
13/11/202421:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
18/06/202417:35GlobeNewswire Inc.XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerNASDAQ:XBITXBiotech Inc
07/02/202418:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
05/01/202416:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
04/01/202415:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
14/11/202315:00GlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
26/09/202315:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
30/08/202315:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
08/08/202317:47GlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
26/06/202314:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
23/06/202321:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
20/06/202315:20Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
22/05/202315:00GlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
17/05/202315:22Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:XBITXBiotech Inc
17/05/202315:00GlobeNewswire Inc.XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesNASDAQ:XBITXBiotech Inc
10/05/202321:42Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
28/04/202318:38Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:XBITXBiotech Inc
28/04/202318:33Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XBITXBiotech Inc
10/02/202318:22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
13/10/202218:46GlobeNewswire Inc.XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerNASDAQ:XBITXBiotech Inc
20/06/202215:00GlobeNewswire Inc.XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer StudyNASDAQ:XBITXBiotech Inc
13/05/202221:17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XBITXBiotech Inc
28/04/202215:00GlobeNewswire Inc.XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal CanceNASDAQ:XBITXBiotech Inc
15/03/202222:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XBITXBiotech Inc
02/02/202215:00GlobeNewswire Inc.XBiotech Inks Clinical Manufacturing DealNASDAQ:XBITXBiotech Inc
13/12/202114:00GlobeNewswire Inc.FDA Approves XBiotech’s IND in RheumatologyNASDAQ:XBITXBiotech Inc
28/10/202117:59GlobeNewswire Inc.XBiotech to Launch Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
08/09/202115:00GlobeNewswire Inc.Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic CancerNASDAQ:XBITXBiotech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XBIT

La tua Cronologia

NASDAQ
FTNT
Fortinet
NYSE
WSR
Whitestone REIT
NASDAQ
FMST
Foremost Clean Energy
AQEU
DIMP
Sartorius Stedim Biotech
COIN
SHXEUR
Stronghold Token
BIT
STMMI
ST Microelectronics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network